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IL-6 and sonic hedgehog (Shh) signaling molecules are considered to maintain the growth of cancer stem cells (CSCs). Resveratrol,
an important integrant in traditional Chinesemedicine, possesses certain antitumor effects.However, themechanisms on regulating
acute myeloid leukemia (AML) are unclear. This study first used human subjects to demonstrate that the plasma levels of IL-6 and
IL-1𝛽 in AML patients were higher and lower, respectively, than healthy donors. The expression of Shh preproproteins, and C- and
N-terminal Shh peptides increased in bone marrow and peripheral blood mononuclear cells isolated from AML patients, and the
plasma N-Shh secretion was greater. To further clarify the effect of IL-6 and resveratrol in Shh signaling, human AML HL-60 cells
were tested. IL-6 upregulated Shh andGli-1 expression andwas accompanied by an increase of cell viability. Resveratrol significantly
decreased CSC-related Shh expression, Gli-1 nuclear translocation, and cell viability in IL-6-treated HL-60 cells and had synergistic
effect with Shh inhibitor cyclopamine on inhibiting cell growth. Conclusions. IL-6 stimulated the growth of AML cells through Shh
signaling, and this effect might be blocked by resveratrol. Further investigations of Shh as a prognostic marker and resveratrol as a
therapeutic drug target to CSCs in AML are surely warranted.
1. Introduction
Recent investigation support the existence of cancer stem
cells (CSCs) in human cancers, suggesting that CSCs may
arise from mutated progenitor cells and then develop the
capacity of unregulated self-renewal [1, 2]. Therefore, CSCs
are a small number of self-renewing tumor cells that
undergo multilineage differentiation and survive in support-
ive microenvironments [3, 4]. The first study of leukemia
stem cells (LSCs) demonstrated that a subpopulation of
acute myeloid leukemia (AML) cells, defined as CD34+
CD38− and shared similar cell surface marker expression
patterns with normal hematopoietic progenitor cells, may
cause the malignancies continue to relapse as a consequence
of resistance to chemotherapies [5, 6].
The intercellular signaling mechanisms for CSC mainte-
nance may involve Wnt/𝛽-catenin, Hedgehog (Hh) pathway,
as well as epigenetic, metabolic, and molecular chaperone
pathways [7]. Among these, the Hh signaling pathway is
a crucial regulator of embryogenesis and development in
adult hematopoietic, neural, skin and hair follicle stem
cells [8, 9]. The Hh signaling pathway, initiated through
the binding of secreted Hh ligands (Sonic, Indian, and
Desert) to the membrane receptor patched (PTCH), results
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in nuclear translocation and activation of the transcription
factors of the Gli family [10]. In leukemia, Hh signaling
is also important in the maintenance of neoplastic stem
cells in the haematopoietic system, raising the possibility of
drug resistance and disease recurrence [11]. The inhibition of
sonic hedgehog (Shh) signaling downregulates the expression
of the ATP-binding cassette transporter multidrug resistant
(MDR) proteins, and thus may be a target for overcoming
drug resistance and increasing the likelihood of response to
chemotherapy [12]. Our previous study demonstrated that
Shh signalingmolecules expressed in human chronicmyeloid
leukemia (CML) cells may regulate Bcr-Abl activation [13].
In addition, a research indicated that thalidomide reduces
vascular endothelial growth factor (VEGF) and interleukin
(IL)-6 expression in the tumor microenvironment accounts,
as well as attenuates Hh signaling activity in advanced
prostate cancers [14].
Growth factors and cytokines released in the bone mar-
row (BM), thymus, and other immune tissue microenvi-
ronments provide the paracrine and autocrine effects for
long-term hematopoietic regulation of stem cells [15]. Such
microenvironment-derived cytokines also play a key role
in maintaining the growth of tumors [16]. For example,
upregulating IL-8 in the marrow microenvironment and
CXCL12/CXCR4 axis may control the pathogenesis of T-cell
acute lymphoblastic leukemia [16]. Peroxisome proliferator-
activated receptor gamma (PPARgamma) negatively controls
multiple myeloma growth, in part through the inhibition
of IL-6 production by marrow stromal cells [17]. In CML
K562 cells, treatment with BM stromal-derived conditioned
medium caused the cells’ resistance to the therapeutic drug
imatinib mesylate (IM, also named STI571), an effect which
correlated with increased IL-6-related phospho-Stat3 expres-
sion [15].
Resveratrol (3,5,4󸀠-trans-trihydroxystilbene) is a phyto-
chemical that widely found in plants (such as grape skin,
red wine, cranberries, blueberries, and peanuts) and in
traditional Chinese medicines (TCMs, such as Rheum offic-
inale Baill. and Polygonum cuspidatum) [18, 19]. Resveratrol
possesses cytotoxic and apoptotic controlling on various
types of cancer and normal cells [20]. Our previous study
reported that resveratrol regulates the apoptosis induction
and erythrocytic differentiation through the modulation of
nuclear factor-kappaB in human leukemia cells [21]. In CML,
resveratrol acts as a Bcr-Abl inhibitor and suppresses Shh
signaling in both IM-sensitive and IM-resistant cells [13].
Resveratrol also reverses doxorubicin-mediated resistance in
AML cells via the downregulation of multidrug resistant
protein (MRP)-1 expression [22]. However, little is known of
resveratrol on regulation of CSCs in AML.
Cancer cells secrete various cytokines to maintain their
microenvironment, stimulate certain signal pathways in
CSCs, thereby increase their survival rate and resistance
to chemotherapy [23]. However, the regulatory effects of
cytokines on Hh-related molecules in the setting of AML are
unclear. In this study, we first brought in human subjects,
including control donors and patients with AML, to examine
the expression of Shh signaling molecules and cytokines in
BM cells and peripheral blood. We subsequently performed
an in vitro assay to clarify the effect of IL-6 on regulating Shh
signaling and assess the possibility of resveratrol used as a
potent Shh inhibitor in AML.
2. Materials and Methods
2.1. Subjects and Isolation of Mononuclear Cells (MNCs) from
Bone Marrow (BM) and Peripheral Blood (PB). Twenty-
six healthy volunteers (six for BM and twenty for PB
collection) and twenty-six patients with AML (M3 type
excluded, six for BM and twenty for PB collection) with
ages ranging from 21–88 years were recruited. All patients
had either newly diagnosed or recently relapsed AML before
anticancer chemotherapeutic treatment. Characteristics of
AML patients were listed in Table 2. Our study design was
approved by the Institutional ReviewBoard (IRB) of Buddhist
Dalin Tzu Chi General Hospital, Taiwan (No. B09703022).
All control donors and patients provided written informed
consent prior to any testing. Patients’ information was not
revealed in this study, and the data were analyzed anony-
mously. Mononuclear cells (MNCs) were separated from BM
or PB on a density gradient (Histopaque, 1.077 g/mL, Sigma,
St. Louis, MO) followed by centrifugation at 2,000 rpm for
15min. The plasma samples isolated from PB were collected
for cytokine detection and Shh expression.
2.2. Measurement of Cytokine Levels in Plasma. Plasma
levels of cytokines, including GM-CSF, IL-1𝛽, TNF-𝛼, and
IL-6 from the control donors and AML patients, were
assayed using a BioSource Multiplex Bead Immunoassay
kit (BioSource International, Inc., Camarillo, CA) with the
Luminex xMAP (Luminex Corp., Austin, TX) instrument
and software program for data analysis.The assaymethodwas
performed according to the manufacturer’s protocol.
2.3. Western Blot Analysis. To measure Shh expression, total
proteins isolated from BM cells, PB-MNCs, and plasma
from human subjects, as well as human leukemia HL-60
cell line. The concentrations of the collected proteins were
quantified using a bicinchoninic acid (BCA) protein assay
kit (Bio-Rad). The same amount of protein (100 𝜇g per well)
was disrupted with 2x concentrated electrophoresis sample
buffer (1M Tris, pH 6.8, 5% SDS, 40% glycerol, 0.005%
bromophenol blue, 8% 𝛽-mercaptoethanol) and subjected to
10% SDS-polyacrylamide gel electrophoresis. The protein gel
was transferred to a PVDF membrane, blotted with primary
antibodies, including anti-Shh (1 : 200, Santa Cruz), anti-
Smo (1 : 200, Santa Cruz), anti-Gli-1 (1 : 200, Santa Cruz),
anti-𝛽-actin (1 : 1000, Santa Cruz), and anti-glyceraldehyde-
3-phosphate dehydrogenase (GAPDH, 1 : 1000, Santa Cruz),
and then incubated at 4∘C for overnight. The membrane
was further hybridized with horseradish peroxidase (HRP)-
conjugated secondary antibody (1 : 1000, Santa Cruz) for 1.5 h
followed by exposing with enhanced chemiluminescence
(Perkin Elmer, Waltham, MA). Relative protein levels were
determined by densitometry using ImageJ software (Version
1.36b, NIH, Bethesda, MD). Relative values were normalized
to the internal control.
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2.4. AML Cell Line and Cell Culture. To clarify the possible
roles of IL-6 and Shh signaling inAML, a humanAMLHL-60
cell line was used for in vitro assay. HL-60 cells were obtained
from American Type Culture Collection (ATCC, Manassas,
VA) andmaintained in RPMI 1640medium (Gibco Products,
Carlsbad, CA) containing 10% (v/v) fetal bovine serum (FBS)
(Gibco) and 2mM L-glutamine (Sigma) in a 37∘C incubator.
For the in vitro assay, cells (2 × 105 cells/mL) were treated
with recombinant human IL-6 (0–10 ng/mL; Cytolab Ltd.,
Rehovot, Israel), cyclopamine (2 𝜇M, Sigma), humanized
anti-human IL-6 receptor antibody (MRA, 100 nM, Chugai
Pharmaceutical Co., Ltd.), and/or various concentrations of
resveratrol (0–50𝜇M, Sigma) for 24 h. For the analysis of
Shh/Gli-1 expression, total RNA and proteins were extracted
from the cells and then adjusted for reverse transcription-
polymerase chain reaction (RT-PCR) and Western blot anal-
ysis. Viable cells were counted using a trypan blue dye
exclusion test. The translocation of Gli-1 was also assayed
using immunofluorescence staining and Western blotting of
the nucleic and cytosolic Gli-1 levels.
2.5. RT-PCR Assay of Shh and Gli-1 Expression. AML HL-
60 cells were treated with IL-6 (0–10 ng/mL) in the addition
with or without MRA (100 nM) for 24 h; then, total RNAs
were isolated from the cells using TRIzol reagent (Life
Technologies, Gaithersburg, MD) and reverse transcribed
to cDNA by reaction in a PCR thermal cycler (Bio-Rad,
Hercules, CA) for 10min at 25∘C, 70min at 37∘C, 10min at
72∘C and stored at 4∘C. Shh, Gli-1, and GAPDH genes were
amplified by PCR using specific primers (Mission Biotech.,
Taipei, Taiwan) and PCR thermal cycle profiles as listed in
Table 1. PCR products were assayed by electrophoresis in a
1% agarose gel in Tris-acetate/EDTA buffer and visualized by
ethidium bromide (0.01%) staining. GAPDH was used for
internal control.
2.6. Preparation of Nuclear and Cytosolic Extracts from Cells.
To prepare the cytosolic and nucleic proteins, the cell nuclei
were first separated from the cytosol using the nuclear
extraction buffer (500mM NaCl, 1.5mM MgCl
2
, 0.2mM
EDTA, 1mM DTT, 20% Glycerol, 0.1% Triton X-100, and
20mM HEPES, pH 7.4). Then, the nuclei were resuspended
in lysis buffer (150mMNaCl, 0.1% SDS, 1% Triton X-100, and
100mM Tris, pH 8.0) and centrifuged at 400 g for 10min.
The nuclear proteins were collected and stored at −80∘C.The
protein concentrations were determined using a BCA protein
assay kit (Bio-Rad), and the levels of cytosolic andnucleicGli-
1 were assayed by Western blotting.
2.7. Immunofluorescence Staining of Gli-1. The treated cells
were collected and reacted with anti-Gli-1 primary antibody
(1 : 200, Santa Cruz Biotechnology, Inc., Heidelberg, Ger-
many) and immunofluorescence PE-conjugated anti-IgG-
TR antibody (1 : 500, Santa Cruz) in order to determine
the distribution of Gli-1 expression in cells. Hoechst 33342
fluorescence dye was also used to stain the location of
the nucleus. The cells were then photographed under a
fluorescence microscope at a magnification of 400x.
2.8. Statistical Analysis. Data were obtained from at least
three independent experiments and expressed as the mean
± standard error (SE). Student’s t-test or analysis of variance
was applied to compare the results for the AML patients
and control donors, as well as the results from the in vitro
studies. Differences were considered significant at P < 0.05.
All statistical analyses were carried out using SigmaStat and
SigmaPlot software (Jandel Scientific, San Rafael, CA).
3. Results
3.1. Plasma Cytokine Production in Control Donors and
AML Patients. Characteristics of AML patients were listed
in Table 2. Among the AML patients, 9 patients died from
cancer within 3 months of blood sample collection. There
was no significant difference in age and gender between
living AML patients and those who died from cancer. In
Figure 1, peripheral blood collected from the AML patients
showed that the AML patient group (n = 20) had a markedly
decreased plasma IL-1𝛽 level (10.0-fold) and an increased
plasma IL-6 level (72.6-fold) as compared to the healthy
volunteers (n = 20). The plasma levels of GM-CSF and TNF-
𝛼 were not different between the control and AML patients.
Moreover, 9 of the 20 patients with AML, who showed
poor prognosis (such as poor quality of life, resistants to
chemotherapy, and higher risk of life threat) and died from
cancer, had higher levels of IL-6 and N-Shh than the patients
who were alive at the same time point (Table 2). The average
age and IL-6 value of normal control were 45.5 ± 8.5 yr old
and 0.8 ± 0.1 pg/mL, respectively.
3.2. Effect of Shh Expression in BM Cells, PB-MNCs, and
Plasma between Control Volunteers and AML Patients. In
Figure 2(a), the expressions of Shh preproproteins (Pre-Shh,
45 kDa), C-terminal (C-Shh, 25 kDa), and N-terminal (N-
Shh, 20 kDa) peptides were all markedly increased in the
BM cells of the AML patients. There was a similar result
in the PB-MNCs from the AML patients, showing greater
expression of Pre-Shh (1.5-fold), C-Shh (1.6-fold), and N-Shh
(1.4-fold) than the cells from the control donors (Figure 2(b)).
However, the expression of smoothened (Smo) did not
significantly differ among these two groups. Western blot
analysis (Figure 2(c)) showed that the soluble Shh secreted
into plasma was significantly increased, along with the active
N-Shh levels, in the AML patient group. Additionally, 9 of
20 patients with AML showed poor prognosis and died from
cancer within 3 months of the blood collection, and they had
higher plasma IL-6 levels and N-Shh expression on testing
than the AML patients who were alive at that point (Table 2).
3.3. Effect of IL-6 on Shh Signaling in Human AML HL-
60 Cells. To clarify the possible regulation of IL-6 and Shh
signaling in AML, a human AML HL-60 cell line was used
for further assay. The mRNA expression of Shh and Gli-1
was estimated with RT-PCR assay (for primers, see Table 1).
Treatment with IL-6 at 5 and 10 ng/mL significantly increased
the mRNA expression of both Shh and Gli-1 in HL-60
cells (Figure 3(a)). The stimulatory effect of IL-6 was also
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Table 1: Primer sequences used for RT-PCR analysis.










aThe PCR thermal cycle profile consisted of 1 cycle of denaturation for 5min at 95∘C; 30 cycles of denaturation for 30 sec at 95∘C, annealing of primers for 45 sec
at different temperatures as shown in this Table, and extension for 50 sec at 72∘C; and 1 cycle of a final extension step at 72∘C for 10min.
Table 2: Characteristics of AML patients (M3 excluded) collected in this study.
Patient
number BM or PB collection Alive or died New diagnose or relapse Type Gender Age (yr) Average values
a
1 BM Alive New diagnose M1 F 58
Age: 46.8 ± 6.5 yr old
2 BM Alive New diagnose M2 M 30
3 BM Alive New diagnose M0 M 53
4 BM Alive New diagnose M2 M 36
5 BM Alive New diagnose M2 F 34
6 BM Alive New diagnose M1 M 70
7 PB Alive New diagnose M2 M 30
Age: 55.5 ± 7.6 yr old
IL-6: 10.1 ± 6.3 pg/mL
N-Shh: 1.7 ± 0.2 fold
8 PB Alive New diagnose M1 M 52
9 PB Alive New diagnose M4 F 84
10 PB Alive New diagnose M1 M 75
11 PB Alive New diagnose M2 M 88
12 PB Alive New diagnose M1 F 60
13 PB Alive New diagnose M2 M 84
14 PB Alive New diagnose M2 M 59
15 PB Alive Relapse M1 F 29
16 PB Alive Relapse M2 M 21
17 PB Alive Relapse M2 M 29
18 PB Died New diagnose M2 M 51
Age: 69.6 ± 2.8 yr old
IL-6: 116.6 ± 54.9 pg/mL∗
N-Shh: 2.4 ± 0.2 fold∗
19 PB Died New diagnose M1 M 80
20 PB Died New diagnose M0 M 71
21 PB Died New diagnose M1 F 69
22 PB Died New diagnose M2 M 78
23 PB Died New diagnose M2 F 75
24 PB Died Relapse M4 M 66
25 PB Died Relapse M2 F 68
26 PB Died Relapse M1 F 68
aThe average age and IL-6 value of normal control were 45.5 ± 8.5 yr old and 0.8 ± 0.1 pg/mL, respectively. The relative fold of N-Shh in AML was normalized
to the normal control, and the data were expressed as mean ± SE.
∗P < 0.05 as compared to the living AML patients. The results were calculated from at least three independent experiments and expressed as mean ± standard
error (SE).

























GM-CSF TNF-𝛼 IL-1𝛽 IL-6
∗
∗
Figure 1: Plasma levels of GM-CSF, TNF-𝛼, IL-1𝛽, and IL-6 in
donors of normal control (n = 20) and AML patients (n = 20) that
analyzed by using a BioSource Multiplex Bead Immunoassay kit.
∗𝑃 < 0.05 as compared to the control group. The results were
calculated from three independent experiments and expressed as
mean ± standard error (SE).
accompanied with the increased expression of Shh proteins,
including Pre-Shh, C-Shh, and N-Shh (Figure 3(b)). Such
stimulatory effect of IL-6 would be blocked in the addition
of MRA (100 nM) in IL-6-treated HL-60 cells (Figure 3(b)).
Moreover, resveratrol effectively decreased the expression
of Pre-Shh, C-Shh, and N-Shh in IL-6-treated HL-60 cells
(Figure 3(c)).
3.4. Viability of Resveratrol and Cyclopamine in IL-6-Induced
HL-60 Cells. In Figure 4(a), IL-6 (10 ng/mL) significantly
increased the viability of HL-60 cells. Resveratrol inhibited
the IL-6-induced cell viability in a dose-dependent manner.
To clarify the roles of IL-6 and Shh signaling in AML, HL-
60 cells were treated with IL-6, Shh inhibitor cyclopamine,
and/or resveratrol for cell viability assay. In Figure 4(b),
cyclopamine significantly decrease the cell viability, as well as
the viability that had been augmented by IL-6. Additionally,
resveratrol enhanced the activity of cyclopamine in HL-
60 cells with and without IL-6 treatment (Figure 4(b)).
As summarized in Figures 3 and 4, IL-6 might stimulate
downstream Shh/Gli-1 signaling that cause the growth of
AML HL-60 cells. Resveratrol has the potential to block this
effect and also has synergistic effect to enhance the inhibitory
effects that induced by cyclopamine.
3.5. Effect of Resveratrol on IL-6-Mediated Gli-1 Nuclear
Translocation in HL-60 Cells. In Figure 5(a), Western blot
analysis of the nucleic and cytosolic Gli-1 expression demon-
strated that IL-6 significantly increased the nucleic Gli-1
expression in the HL-60 cells. Cyclopamine and resveratrol
significantly prohibited the nucleic translocation of Gli-
1 in IL-6-stimulated HL-60 cells (Figure 5(a)). Moreover,
immunofluorescence staining of these treated cells also
showed that IL-6 markedly induced Gli-1 expression in
nucleus of HL-60 cells, while cyclopamine and resveratrol
obviously decreased both the Gli-1 level and Gli translo-
cation to nuclei (Figure 5(b)). Therefore, it was suggested
that resveratrol, like cyclopamine, has potential effect on
inhibition of IL-6-mediated Shh signaling and Gli-1 nuclear
translocation in AML HL-60 cells.
4. Discussion
Leukemia is a common cancer worldwide. Developments
of potential drugs targeted to CSC inhibition that enhance
efficacy and prevent drug resistance are currently the most
principal treatment of leukemia [24]. In CML, IM is designed
to treat patients with Bcr/Abl-containing leukemic cells
[14]. Our previous study reported that Shh signaling might
upregulate Bcr-Abl overexpression and caused the cells more
resistant to IM treatment, while resveratrol acted as a Shh
inhibitor and reversed such resistant effect [13]. In AML,
the present study also demonstrated that the level of IL-6
and Shh were higher in AML patients than normal donors,
and even higher IL-6 and Shh levels in patients who showed
poor prognosis (such as poor quality of life, resistant to
chemotherapy, and higher risk on life threat) and died from
cancer. This study excluded AML-M3 patient, because of a
notable difference between M3 and other AMLs involved
the common occurrence of life-threatening consumptive
coagulopathies in M3 patients that dramatically affected
patient outcomes [25].
Both IL-6 and Shh are important in the maintenance of
CSCs in the neoplasticmicroenvironment, limiting the access
of therapeutics to the tumor, alter drug metabolism, and
contribute to the development of drug resistance and disease
recurrence [11, 14, 26]. Kobune et al. indicated that aberrant
Hh pathway activation is a feature of some CD34+ myeloid
leukemic cells, and Hh inhibitors may have a therapeutic
role in the treatment of AML [27]. Here, we studied the
correlation between Shh signaling and IL-6 regulation in
myeloid leukemia. AML HL-60 cells were treated with IL-6
and subsequently assayed for the expression of Shh and Gli-
1 genes. IL-6 significantly increased the expression of both
Shh and Gli-1, as well as cell viability, demonstrating that
upstream regulation of IL-6 may initiate cellular Shh/Gli-
1 signaling pathways and cause growth in the AML cells.
Such effect was confirmed by the treatment of MRA, a
humanized anti-human IL-6 receptor antibody, with block-
ing activity on IL-6-mediated Shh signaling. In addition,
the Shh inhibitor cyclopamine significantly decreased the
viability and Gli-1 translocation of IL-6-treated HL-60 cells,
hinting that blocking the Shh pathway may be a potential
strategy for AML treatment. An article reported that up
to 40% of hepatocellular carcinomas are potentially arising
from stem cells and increased activation ofmultiple pathways
including IL-6/STAT3, WNT, CDK4, and the Hh signaling
pathway [28]. In gastric cancer patients, chronicHelicobacter
pylori infection elevated IL-1𝛽, IL-6, IL-8, TNF-𝛼, and IFN-
𝛾 in the gastric mucosa, as well as activating the stem
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Figure 2: Expression of Shh preproprotein (pre-Shh), C-terminal (C-Shh), and N-terminal (N-Shh) in (a) bone marrow (BM) cells, (b)
peripheral blood mononuclear cells (PB-MNCs), and (c) plasma collected from the normal control donors and the AML patients using
a Western blot analysis. The relative values were normalized to the internal control 𝛽-actin, and the data were expressed as mean ± SE.
∗𝑃 < 0.05 as compared to the control group.





































































































Figure 3: Regulation of IL-6 and resveratrol in Shh signaling in AML HL-60 cells. (a) RT-PCR assay of Shh and Gli-1 expressed in HL-60
cells with the treatment of IL-6 (5 and 10 ng/mL) for 24 h. (b) Western blot analysis of Shh preproproteins (Pre-Shh, 45 kDa), C-terminal
(C-Shh, 25 kDa), and N-terminal (N-Shh, 20 kDa) peptides in IL-6-treated HL-60 cells with or without MRA (100 nM) treatment. (c) Effect
of resveratrol on Shh expression in IL-6-treated HL-60 cells.The relative values were normalized to the internal control, were calculated from
three independent experiments, and were expressed as mean ± SE. ∗𝑃 < 0.05 as compared to the control group. #𝑃 < 0.05 as compared to
the IL-6 alone group.
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Figure 4: Viability of IL-6, cyclopamine, and resveratrol in HL-60 cells that assayed by using a trypan blue dye exclusion test. (a) Viability of
resveratrol in IL-6-treated HL-60 cells. (b) Cell viability assay of IL-6 (10 ng/mL), cyclopamine (2𝜇M), and resveratrol (25𝜇M). The results
were calculated from three independent experiments andwere expressed asmean± SE. ∗𝑃 < 0.05 as compared to the control group. #𝑃 < 0.05
as compared to the IL-6 alone group.
cell signaling network, consisting of the WNT, Notch, FGF,
Hh, and BMP signaling pathways [29]. Our study is the
first to demonstrate that IL-6 production in AML would
stimulate the downstream Shh signaling pathway and induce
the growth of leukemia cells. Modulating Shhmolecules with
their antagonists, such as cyclopamine, may prove to be a
strong therapeutic option for AML patients.
More and more chemopreventive natural products (such
as soy, genistein, resveratrol, catechin, and curcumin) are
suggested for the reversal of adverse epigenetic marks in
cancer cells andCSCs to attenuate tumorigenesis progression,
prevent metastasis, or sensitize for drug sensitivity [30].
Resveratrol, a natural phytoalexin widely presented in foods
and TCMs [18, 19], has multiple biological functions that
affect cell growth, anti-inflammation, apoptosis, angiogene-
sis, and metastasis [31]. Herbal medicines with resveratrol-
containing, such as Rheum officinale Baill. and Polygonum
cuspidatum, have been widely used in TCM for eliminating
inflammatory response and reducing tumor growth [32,
33]. It was suggested that these TCMs may have certain
capacity to regulate tumor microenvironment and inhibit
CSC characteristics. An article reported that treatment of
resveratrol effectively inhibited the cancer stem-like cell
properties and radioresistance of CD133+-glioblastoma mul-
tiforme (GBM) cells [34]. Resveratrol inhibits pancreatic CSC
characteristics in human and Kras(G12D) transgenic mice by
inhibiting pluripotency maintaining factors and epithelial-
mesenchymal transition [35]. In this study, resveratrol
decreased the cell viability that augmented by CSC-related
factor IL-6 and decreased the expression of CSC-specific
Shh signaling in IL-6-treated HL-60 cells. Like Shh inhibitor
cyclopamine, resveratrol significantly prohibited the Gli-1
expression and nucleic translocation in IL-6-stimulated HL-
60 cells. Similar researches of resveratrol on CSC effect also
reported that resveratrol and several dietary compounds that
possess potential effect against CSCs through the regulation
of self-renewal pathways, including Wnt/𝛽-catenin, Hh, and
Notch pathways [36, 37]. Therefore, it was suggested that
resveratrol might have potential inhibitory properties of
CSC-related IL-6 and Shh molecule expression in AML cells.
5. Conclusions
The present study is the first to discover that AML patients
were associated with elevated expression of CSC-related IL-6
and Shh molecules in marrow and/or blood compared with
the control donors. We found in subsequent experiments
that IL-6 stimulated downstream Shh/Gli-1 signaling and
caused an increase in cell viability in AML cells. The TCM
component resveratrol, like the Shh inhibitor cyclopamine,
effectively prohibited the IL-6-mediated cell growth and
Shh signaling in AML. The increased production of IL-6 in
patients with AML may stimulate the Shh signaling pathway
and increase the risk of unfavorable prognosis, implying
that further investigation of new drugs (such as resveratrol)
targeted to block Shh may prove to be beneficial for patients
with AML.
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Figure 5: Effect of cyclopamine and resveratrol on Gli-1 nuclear translocation in HL-60 cells with or without IL-6 treatment. (a) Expression
of nucleic and cytosolic Gli-1 using a Western blot analysis. The relative values were normalized to the internal control, were calculated from
three independent experiments, and were expressed as mean ± SE. (b) Immunofluorescence staining of Gli-1.These cells were double stained
with PE-conjugated anti-Gli-1 antibody (red) and Hoechst 33342 fluorescence dye (blue, nucleus). ∗𝑃 < 0.05 as compared to the control
group. #𝑃 < 0.05 as compared to the IL-6 alone group.
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